Kris Vaddi, Ph.D.

Kris Vaddi, Ph.D. founded Prelude Therapeutics and has served as the Chief Executive Officer and member of the Board of Directors since 2016. Prior to founding Prelude, from 2014 to 2016, Dr. Vaddi served as Chief Executive Officer of Orsenix, LLC, a clinical stage biotechnology company. Previously, he held several roles at Incyte Corporation, starting as a Founding Scientist and an Executive Director in 2002, and most recently as a Senior Advisor from 2015 to 2016. Dr. Vaddi initiated and championed JAK research programs at Incyte that led to the discovery, development, and approval of JakafiĀ®(ruxolotinib) for Myelofibrosis and Polycythemia Vera and OlumiantĀ®(baricitinib) for rheumatoid arthritis. He received his BVSc in Veterinary Medicine from APAU in India and his Ph.D. in Pharmacology and Toxicology from University of Florida.